ALVELESTAT
Alvelestat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against neutrophil elastase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | 5 | — | — | — | 7 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 2 | 4 | — | — | — | 6 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 4 | — | — | — | 4 |
| Covid-19 | D000086382 | — | — | 1 | 2 | — | — | — | 2 |
| Graft vs host disease | D006086 | — | D89.81 | 2 | 2 | — | — | — | 2 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | 2 | — | — | — | 2 |
| Alpha 1-antitrypsin deficiency | D019896 | — | E88.01 | — | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALVELESTAT |
| INN | alvelestat |
| Description | Alvelestat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against neutrophil elastase. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: elastase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1240425-05-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3617964 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6Y5629322X (ChemIDplus, GSRS) |
Target
Agency Approved
ELANE
ELANE
Organism
Homo sapiens
Gene name
ELANE
Gene synonyms
ELA2
NCBI Gene ID
Protein name
neutrophil elastase
Protein synonyms
Bone marrow serine protease, elastase 2, neutrophil, Elastase-2, granulocyte-derived elastase, HLE, Human leukocyte elastase, leukocyte elastase, Medullasin, PMN elastase, polymorphonuclear elastase, polymorphonuclear leukocyte elastase
Uniprot ID
Mouse ortholog
Elane (50701)
neutrophil elastase (Q61515)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 239 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use